News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

NeoGenomics Laboratories Extends Its Cancer Testing Services Through Exclusive Agreement with Response Genetics, Inc.

9/29/2008 11:35:20 AM

FORT MYERS, Fla., Sept. 29 /PRNewswire-FirstCall/ -- NeoGenomics Laboratories , a national clinical reference laboratory specializing in high-complexity, cancer-specific testing, announced today an exclusive agreement with Response Genetics Inc. to offer its proprietary ResponseDX: Colon(TM) and ResponseDX: Lung(TM) tests nationwide. ResponseDX: Colon(TM) and ResponseDX: Lung(TM) are proprietary PCR-based tests in a cost-effective panel format which serve to help oncologists make optimal therapeutic treatment decisions for patients with colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).

Under the terms of the agreement, NeoGenomics will be the exclusive national clinical reference laboratory authorized to offer Response Genetics' proprietary tests as a complement to Response Genetics newly formed sales team. Response Genetics proprietary ResponseDX(TM) panels include analysis of the K-ras (KRAS) mutation, gene expression profiling of RRM1 and up to three other patent-protected genes: ERCC1, TS, and EGFR. KRAS is a strong predictor of whether patients will respond or not respond to the common treatment regimens for these types of cancers. KRAS is fast becoming a testing standard for patients with advanced or metastatic colorectal cancer. Likewise, expression results of the other genes in the ResponseDX(TM) panels can help oncologists choose among several other standard chemotherapy regimens to treat their patients specifically by the biology of their disease which allows for a more targeted intervention.

Response Genetics provides the fastest turn-around times in the industry for these types of molecular tests. Importantly, their standards are compatible with our own industry leading turn-around times which makes for a very synergistic combined product offering. In addition, by using a cutting edge technique known as micro-dissection, Response Genetics obtains the most accurate results on the smallest of biopsies; something other labs offering this type of testing cannot do. In many cases no tissue samples other than the pre-treatment diagnostic biopsy will be required for the complete gene expression analysis which is a significant benefit to patients as they won't have to undergo a second biopsy in order to reap the benefits of this test. All tests will be performed in Response Genetics' CLIA-certified laboratory in Los Angeles, CA.

Robert P. Gasparini, NeoGenomics' President and Chief Scientific Officer, commented, "Most laboratory pundits agree that the future of clinical laboratory testing continues to move towards genomics-based technologies, such as those being pioneered by Response Genetics. We could not be more pleased than to have Response Genetics as a partner in this endeavor. Their intellectual property position, publication record, and experience derived in clinical trial testing with tens of thousands of specimens represents a formidable barrier to competitive entry and bodes well for the marketplace introduction of these new predictive tests. We believe that the Response DX(TM) panels have the potential to quickly become the standard of care with regard to lung and colorectal cancer testing and that there will be significant interest in these new tests from both our existing and new clients. The addition of these panels to our product line-up allows us to further differentiate our services and offer more comprehensive one-stop shopping for our clients. We are particularly excited about the opportunity to attract new clients with the ResponseDX(TM) panels and then offer them the rest of NeoGenomics' industry leading genetic and AP testing services."

"We are extremely pleased to be working with NeoGenomics Laboratories to expand the availability of our ResponseDX(TM) tests to the national marketplace," said Kathleen Danenberg, Response Genetics' President and CEO. "Through the strength of the two companies' sales organizations, we will work together to introduce Response Genetics' proprietary technologies to help make personalized medicine a reality for cancer patients today with these diseases."

About NeoGenomics

NeoGenomics Laboratories is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit .

About Response Genetics

Response Genetics, Inc. ("RGI") (the "Company") is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. In addition to diagnostic testing services, RGI generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit .

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

CONTACT: Steven C. Jones, Director of Investor Relations of NeoGenomics
Laboratories, +1-239-325-2001,; or Julie Marshall of
Hawk Associates, Inc. for NeoGenomics Laboratories, +1-305-451-1888,

Web site:

Read at

comments powered by Disqus